Cantor Fitzgerald reaffirmed their overweight rating on shares of Flexion Therapeutics Inc (NASDAQ:FLXN) in a research report report published on Saturday morning. They currently have a $34.00 target price on the specialty pharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on the company. Zacks Investment Research upgraded Flexion Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 14th. Royal Bank of Canada restated an outperform rating and set a $44.00 target price on shares of Flexion Therapeutics in a research report on Saturday, March 11th. Janney Montgomery Scott restated a buy rating and set a $30.00 target price on shares of Flexion Therapeutics in a research report on Saturday, March 11th. BMO Capital Markets restated a positive rating and set a $33.00 target price on shares of Flexion Therapeutics in a research report on Tuesday, February 7th. Finally, Raymond James Financial, Inc. assumed coverage on Flexion Therapeutics in a research report on Thursday, December 22nd. They set a strong-buy rating and a $35.00 target price on the stock. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $28.68.

Flexion Therapeutics (NASDAQ:FLXN) traded down 2.19% during midday trading on Friday, reaching $26.37. The company had a trading volume of 322,925 shares. Flexion Therapeutics has a 52-week low of $8.16 and a 52-week high of $29.41. The company’s 50-day moving average is $24.28 and its 200 day moving average is $20.44. The company’s market cap is $836.75 million.

Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings data on Thursday, March 9th. The specialty pharmaceutical company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.07. On average, equities research analysts forecast that Flexion Therapeutics will post ($3.50) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/04/21/flexion-therapeutics-inc-flxn-receives-overweight-rating-from-cantor-fitzgerald-updated-updated.html.

In related news, insider Neil Bodick sold 5,000 shares of the stock in a transaction on Monday, April 17th. The stock was sold at an average price of $28.23, for a total value of $141,150.00. Following the transaction, the insider now owns 46,137 shares of the company’s stock, valued at $1,302,447.51. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Frederick W. Driscoll sold 3,000 shares of the stock in a transaction on Thursday, March 23rd. The shares were sold at an average price of $23.00, for a total value of $69,000.00. Following the completion of the transaction, the chief financial officer now directly owns 10,777 shares in the company, valued at approximately $247,871. The disclosure for this sale can be found here. In the last three months, insiders sold 18,000 shares of company stock worth $407,950. 18.00% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FLXN. Peregrine Capital Management LLC bought a new position in shares of Flexion Therapeutics during the third quarter worth about $14,126,000. Kingdon Capital Management L.L.C. boosted its position in shares of Flexion Therapeutics by 29.2% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 1,379,486 shares of the specialty pharmaceutical company’s stock worth $26,238,000 after buying an additional 311,865 shares during the period. Novo A S boosted its position in shares of Flexion Therapeutics by 27.3% in the fourth quarter. Novo A S now owns 1,397,718 shares of the specialty pharmaceutical company’s stock worth $26,585,000 after buying an additional 300,000 shares during the period. Alyeska Investment Group L.P. bought a new position in shares of Flexion Therapeutics during the fourth quarter worth about $4,755,000. Finally, State Street Corp boosted its position in shares of Flexion Therapeutics by 27.6% in the fourth quarter. State Street Corp now owns 391,606 shares of the specialty pharmaceutical company’s stock worth $7,449,000 after buying an additional 84,770 shares during the period. 62.25% of the stock is currently owned by institutional investors and hedge funds.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

5 Day Chart for NASDAQ:FLXN

Receive News & Stock Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related stocks with our FREE daily email newsletter.